Zobrazeno 1 - 10
of 12
pro vyhledávání: ''
Autor:
Yi Li, Guojun Yue, Hui Dong, Yunliang Cao, Fang Chen, Qiaoyuan Wu, Qing Luo, Yudi Dong, Ni Jiang
Publikováno v:
Anti-Cancer Drugs
Since the treatment of lung squamous cell carcinoma (SCC) was limited due to a lack of appropriate biomarkers and novel target agents. Immune checkpoint inhibitors can offer an effective treatment for patients with advanced non-small cell lung cancer
Publikováno v:
Anti-Cancer Drugs
Programmed cell death protein 1 (PD-1) inhibitors have demonstrated promising activity among patients with advanced soft tissue sarcomas (STS) in phase II trials. The purpose of this study was to assess the efficacy and safety of toripalimab (a novel
Autor:
Inés, González-Barrallo, Victoria Eugenia, Castellón Rubio, Javier, Medina, Sofia, España, Karmele, Mujika, Margarita, Majem, Carlos, Aguado, Miguel Ángel, Cabrera Suárez, Isabel, Palacio, Lisa, Osterloh, Alejandro, Martínez-Fernández, Almudena, García-Castaño
Publikováno v:
MELANOMA RESEARCH
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Melanoma Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Melanoma Research
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Efficacy and safety of dabrafenib and trametinib in metastatic melanoma have been demonstrated in two-phase III and one-phase I/II clinical trials. However, patients at least 75 years old (y.o.) were largely underrepresented. Additionally, the safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68956426c153adc2ab95246fa352fb48
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13002
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13002
Autor:
Shugeng Gao, Xuemin Xue, Qing Fang, Wenbin Li, Liankui Han, Changyuan Guo, Lei Guo, Jianming Ying, Peng Song
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
The effect of chemotherapy on programmed cell death-ligand 1 (PD-L1) expression has been previously studied in lung cancer, while the results remain controversial. The aim of this study was to investigate the variation of PD-L1 expression after neoad
Publikováno v:
Medicine
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related mortality globally. Abnormal DNA methylation is closely related to gastric cancer. The purpose of the study was to investigate the methylation of the SYNE1 a
Autor:
Hyungwoo Cho, Kyu-Pyo Kim, Hong Seok Jang, Jeong Eun Kim, Jong Hoon Kim, Myung Ah Lee, Tae-Won Kim, Dae Yong Kim, Yong Sang Hong, Jin Cheon Kim, Jae Hwan Oh, Sun-Young Kim, Seong Taek Oh, Chang Sik Yu
Publikováno v:
American Journal of Clinical Oncology
Supplemental Digital Content is available in the text.
Objectives: Controversy surrounds the management of patients with locally advanced rectal cancer with synchronous resectable liver metastases (LMs). This study was designed to improve both s
Objectives: Controversy surrounds the management of patients with locally advanced rectal cancer with synchronous resectable liver metastases (LMs). This study was designed to improve both s
Autor:
Thomas Olencki, Gregory B. Lesinski, Sanaa Tahiri, Kari Kendra, Amir Mortazavi, Thomas A. Mace, Susan Geyer, William E. Carson, Arvinder Bhinder, Steven K. Clinton, Elaine T. Lam, Paul Monk
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
This study was designed to evaluate the safety and feasibility of high-dose interleukin-2 (HD IL-2) followed by sorafenib in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC). Biomarkers relevant to the antitumor effects of IL-2 t
Autor:
Miguel Gil-Gil, Gaspar Reynes, Pedro Pérez-Segura, Isabel Palomero, Virtudes Vila, Oscar Gallego, Manuel Benavides, Vicenta Martínez-Sales, Encarnación Reche, Carmen Balana, M.A. Vaz, Tania Fleitas
Publikováno v:
ANTI-CANCER DRUGS
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
This phase II study was conducted to determine the efficacy and safety of metronomic temozolomide (TMZ) in combination with irinotecan in glioblastoma (GB) at first relapse. Patients with GB at first relapse received TMZ 50 mg/m(2)/day divided into t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8575790b211e64bbda3eda69868699d4
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3090
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=3090
Autor:
Gaspar Reynes, José Alejandro Lugo García, Pedro Yobanis Piñero Pérez, Carmen Balana, Luis Iglesias, Oscar Gallego
Publikováno v:
ANTI-CANCER DRUGS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
To determine the maximum tolerated dose of irinotecan administered every 2 weeks, in combination with a fixed and continuous administration of temozolomide, in patients with glioblastoma at first relapse. Patients received oral temozolomide at a fixe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c78ecc3d34b6bd4bdc96e863b944551c
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8677
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8677
Autor:
G. Stoter, A. van der Gaast, Peter D. Siersema, Ted A.W. Splinter, M. B. Polee, H. W. Tilanus, T. C. Kok
Publikováno v:
Anti-Cancer Drugs, 12(6), 513-517. Lippincott Williams & Wilkins
The objective of this study was to determine the toxicity and the efficacy of the combination of cisplatin, etoposide, 5-fluorouracil (5-FU) and folinic acid in the treatment of patients with advanced squamous cell carcinoma of the esophagus. Patient